Follow
Robert J Fox
Robert J Fox
Mellen Center for Multiple Sclerosis, Cleveland Clinic
Verified email at ccf.org - Homepage
Title
Cited by
Cited by
Year
Defining the clinical course of multiple sclerosis
FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ...
Neurology 83 (3), 278-286, 2014
8038*2014
Defining the clinical course of multiple sclerosis: the 2013 revisions
FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ...
Neurology 83 (3), 278-286, 2014
36812014
Defining the clinical course of multiple sclerosis: the 2013 revisions
FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ...
Neurology 83 (3), 278-286, 2014
36812014
B-cell depletion with rituximab in relapsing–remitting multiple sclerosis
SL Hauser, E Waubant, DL Arnold, T Vollmer, J Antel, RJ Fox, A Bar-Or, ...
New England Journal of Medicine 358 (7), 676-688, 2008
27272008
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
RJ Fox, DH Miller, JT Phillips, M Hutchinson, E Havrdova, M Kita, M Yang, ...
New England Journal of Medicine 367 (12), 1087-1097, 2012
15592012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
RJ Fox, DH Miller, JT Phillips, M Hutchinson, E Havrdova, M Kita, M Yang, ...
New England Journal of Medicine 367 (12), 1087-1097, 2012
15592012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
RJ Fox, DH Miller, JT Phillips, M Hutchinson, E Havrdova, M Kita, M Yang, ...
New England Journal of Medicine 367 (12), 1087-1097, 2012
15592012
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients
R Dutta, J McDonough, X Yin, J Peterson, A Chang, T Torres, T Gudz, ...
Annals of neurology 59 (3), 478-489, 2006
9642006
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
9382018
Rituximab in relapsing‐remitting multiple sclerosis: a 72‐week, open‐label, phase I trial
A Bar‐Or, PAJ Calabresi, D Arnold, C Markowitz, S Shafer, LH Kasper, ...
Annals of neurology 63 (3), 395-400, 2008
5982008
Treatment of neuromyelitis optica with rituximab
A Jacob, BG Weinshenker, I Violich, N McLinskey, L Krupp, RJ Fox, ...
Arch Neurol 65 (11), 1443-8, 2008
5452008
Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic …
LS Brady, HJ Whitfield, RJ Fox, PW Gold, M Herkenham
The Journal of clinical investigation 87 (3), 831-837, 1991
4221991
Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients
R Dutta, A Chang, MK Doud, GJ Kidd, MV Ribaudo, EA Young, RJ Fox, ...
Annals of neurology 69 (3), 445-454, 2011
3532011
MRI findings in Susac’s syndrome
JO Susac, FR Murtagh, RA Egan, JR Berger, R Bakshi, N Lincoff, ...
Neurology 61 (12), 1783-1787, 2003
3452003
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
D Ontaneda, AJ Thompson, RJ Fox, JA Cohen
The Lancet 389 (10076), 1357-1366, 2017
3432017
Multiple sclerosis normal‐appearing white matter: Pathology–imaging correlations
NM Moll, AM Rietsch, S Thomas, AJ Ransohoff, JC Lee, R Fox, A Chang, ...
Annals of neurology 70 (5), 764-773, 2011
3342011
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
BO Khatri, S Man, G Giovannoni, AP Koo, JC Lee, B Tucky, F Lynn, ...
Neurology 72 (5), 402-409, 2009
3182009
Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis
A Salter, RJ Fox, SD Newsome, J Halper, DKB Li, P Kanellis, K Costello, ...
JAMA neurology 78 (6), 699-708, 2021
2662021
Phase 2 trial of ibudilast in progressive multiple sclerosis
RJ Fox, CS Coffey, R Conwit, ME Cudkowicz, T Gleason, A Goodman, ...
New England Journal of Medicine 379 (9), 846-855, 2018
2652018
Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV …
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
The Journal of infectious diseases 197 (8), 1145-1155, 2008
2592008
The system can't perform the operation now. Try again later.
Articles 1–20